|
Kirin and Corixa Announce Alliance to Develop Human Antibody Therapeutics TOKYO, June 21 /PRNewswire/ -- Kirin Brewery Co., Ltd. and Corixa Corporation (Nasdaq: CRXA - news) today announced an agreement to discover and develop fully human antibody therapeutics. Kirin will provide Corixa its TC Mouse(TM) technology, including the KM Mouse(TM) which was co-developed by Kirin and Medarex, Inc., to create human antibodies to multiple target antigens from Corixa`s extensive library of autoimmune disease, cancer and infectious disease antigens. Under the terms of the agreement, Corixa has option rights to exclusively develop and commercialize human antibody products created using the TC Mouse(TM) technology. In return, Kirin will receive certain license fees and milestone payments as well as royalties on commercial sales of antibody products from Corixa. Kirin also retains a first negotiation right to develop and commercialize Corixa`s antibody products from this alliance in Asia. Kirin`s TC Mouse(TM) technology is a transchromosomic mouse system that uses transferred human chromosome fragments carrying 100% of the variable and constant region sequences found in the natural human immunoglobulin gene sequences. |
|
| aus der Diskussion: | Medarex und die Bio´s |
| Autor (Datum des Eintrages): | pollyanna (22.06.01 10:33:03) |
| Beitrag: | 77 von 87 (ID:3794378) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |